Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: A systematic literature review of current and emerging treatment options

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Golan, Yoav ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Carbapenem; Ceftazidime avibactam; Ceftolozane tazobactam; Complicated intra abdominal infection; Complicated urinary tract infection; Piperacillin tazobactam; Tigecycline

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AVIBACTAM PLUS CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; DORIPENEM; ERTAPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPLICATED URINARY TRACT INFECTION; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; GRAM NEGATIVE COMPLICATED INTRA ABDOMINAL INFECTION; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; PSEUDOMONAS AERUGINOSA; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; COMPLICATION; FACTUAL DATABASE; GRAM-NEGATIVE BACTERIAL INFECTIONS; INTRAABDOMINAL INFECTIONS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; DATABASES, FACTUAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84938577959     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1054-1     Document Type: Article

References (41)

1. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Med Chem. 2014;6:25-64.
2. Shlaes DM, Sahm D, Opiela C, Spellberg B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother. 2013;57(10):4605-7.
3. Antibiotic resistance threats in the United States (2013) [ http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf ]
4. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14.
5. Swenson BR, Metzger R, Hedrick TL, McElearney ST, Evans HL, Smith RL, et al. Choosing antibiotics for intra-abdominal infections: what do we mean by "high risk"? Surg Infect (Larchmt). 2009;10(1):29-39.
6. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159-66.
7. Endimiani A, Luzzaro F, Perilli M, Lombardi G, Coli A, Tamborini A, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis. 2004;38(2):243-51.
8. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250-9.
9. Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, de Cueto M, Rios MJ, et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis. 2006;43(11):1407-14.
10. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-64.
11. Zilberberg MD, Shorr AF. Secular trends in Gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol. 2013;34(9):940-6.
12. Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62(9):165-70.
13. Patel TS, Nagel JL. Clinical Outcomes of Enterobacteriaceae Infections Stratified by Carbapenem MICs. J Clin Microbiol. 2015;53(1):201-5.
14. Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg. 2003;237(2):235-45.
15. Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant Gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis. 2011;53 Suppl 2:S33-55. quiz S56-38.
16. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 2004;54(1):144-54.
17. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother. 2004;48(8):3086-92.
18. Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470-80.
19. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab. 2009;10(1):13-21.
20. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41 Suppl 5:S341-53.
21. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55(3):1162-72.
22. Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and beta-lactamase-inhibitor combination. Infec Drug Resistance. 2013;6:215-23.
23. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs. 2014;74(1):31-51.
24. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother. 2013;57(12):6305-10.
25. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55(1):390-4.
26. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens PR, et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013;73(2):159-77.
27. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther. 2008;30(5):868-83.
28. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. Tigecycline 301 Study Group, Tigecycline 306 Study Group: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005;41 Suppl 5:S354-67.
29. Fomin P, Koalov S, Cooper A, Babinchak T, Dartois N, De Vane N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. J Chemother. 2008;20 Suppl 1:12-9.
30. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis. 2005;5:88.
31. Chen Z, Wu J, Zhang Y, Wei J, Leng X, Bi J, et al. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis. 2010;10:217.
32. Qvist N, Warren B, Leister-Tebbe H, Zito ET, Pedersen R, McGovern PC, et al. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial. Surg Infect (Larchmt). 2012;13(2):102-9.
33. Erasmo AA, Crisostomo AC, Yan LN, Hong YS, Lee KU, Lo CM. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian J Surg. 2004;27(3):227-35.
34. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg. 2006;244(2):204-11.
35. Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J, Friedland I, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(9):5350-7.
36. Eckmann C, Hershberger E, Miller B, Wooley M, Friedland I, Steenbergen J, Collins S, Yuan G, Barie P, Solomkin J: P0266a. Efficacy and safety of ceftolozane/tazobactam versus meropenem in the treatment of complicated intra-abdominal infections (cIAI) in hospitalised adults: results from the phase 3 aspect-cIAI trial. [Abstract] In: 24th Annual European Congress of Clinical Microbiology and Infectious Diseases: May 10-13 2014; Barcelona, Spain; 2014. https://www.escmid.org/escmid_library/online_lecture_library/?search=1¤t_page=1&search_term=Christian+Eckmann Accessed 7/30/201
37. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother. 2013;68(5):1183-92.
38. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother. 2009;53(9):3782-92.
39. Redman R, Damiao R, Kotey P, Kaniga K, Davies T, Naber KG. Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis. J Chemother. 2010;22(6):384-91.
40. Wagenlehner F, Umeh O, Huntington J, Cloutier D, Friedland I, Steenbergen J, Yuan G, Yoon M, Darouiche R: eP449. Efficacy and safety of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (CUTI)/pyelonephritis in hospitalised adults: results from the phase 3 aspect-CUTI trial. [Abstract] In: 24th Annual European Congress of Clinical Microbiology and Infectious Diseases: May 10-13 2014; Barcelona, Spain; 2014. https://www.escmid.org/escmid_library/online_lecture_library/?search=1¤t_page=1&search_term=eP449 https://www.escmid.org/escmid_library/online_lecture_library/?search=1¤t_page=1&search_term=eP449. Accessed 7/30/2015
41. Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28(12):1921-31.